Drug intelligence / Profile preview

IMA001

Development stage: Preclinical
Lead developer: Nuvamid
Modality: Small Molecules
Administration: Intraperitoneal

Overview

**IMA001** is a novel small molecule nucleotide developed for the treatment of sickle cell disease (SCD). It targets coenzyme mechanisms central to cellular metabolism, demonstrating efficacy in reducing sickling, improving anemia and hemolysis parameters, and enhancing hematological and vascular outcomes during vaso-occlusive crises (VOCs) in preclinical in vivo models. Initially developed by Nuvamid SA and also associated with Imalia and LGD SARL, it shows potential as a safe therapeutic to address key pathophysiology in SCD, including during acute VOC episodes.[1][2][3][5][9][10]

Beyond the preview

Go deeper on IMA001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMA001.

Explore the full profile